BridgeBio Pharma, Inc.
BBIO
$66.88
$0.931.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 194.52M | 154.18M | 120.70M | 110.57M | 116.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 194.52M | 154.18M | 120.70M | 110.57M | 116.63M |
| Cost of Revenue | 9.94M | 8.11M | 6.56M | 3.65M | 2.64M |
| Gross Profit | 184.58M | 146.07M | 114.14M | 106.91M | 113.99M |
| SG&A Expenses | 163.90M | 158.09M | 137.62M | 129.15M | 106.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 300.47M | 282.61M | 257.06M | 244.04M | 220.44M |
| Operating Income | -105.96M | -128.43M | -136.36M | -133.47M | -103.80M |
| Income Before Tax | -166.56M | -194.76M | -186.48M | -181.66M | -169.61M |
| Income Tax Expenses | -- | -120.00K | -1.55M | 2.10M | -- |
| Earnings from Continuing Operations | -166.56M | -194.64M | -184.94M | -183.76M | -169.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.51M | 1.77M | 2.19M | 1.86M | 2.19M |
| Net Income | -164.04M | -192.86M | -182.74M | -181.90M | -167.42M |
| EBIT | -105.96M | -128.43M | -136.36M | -133.47M | -103.80M |
| EBITDA | -104.77M | -127.00M | -134.96M | -132.16M | -102.52M |
| EPS Basic | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 |
| Normalized Basic EPS | -0.52 | -0.58 | -0.57 | -0.58 | -0.47 |
| EPS Diluted | -0.84 | -1.00 | -0.95 | -0.95 | -0.88 |
| Normalized Diluted EPS | -0.52 | -0.58 | -0.57 | -0.58 | -0.47 |
| Average Basic Shares Outstanding | 194.79M | 193.55M | 191.85M | 190.52M | 190.15M |
| Average Diluted Shares Outstanding | 194.79M | 193.55M | 191.85M | 190.52M | 190.15M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |